Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter

Pharmaceutical Technology\'s In the Lab eNewsletter-05-01-2019
Volume14
Issue 5

Kit Identifies Endonuclease Impurities for Gene Therapy

Cygnus Technologies has developed the EndonucleaseGTP ELISA Kit to quantitate and detect residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy.

The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy. With a detection limit of ~0.06 ng/mL, the kit is three times more sensitive than the only other commercially available assay for detection and quantitation of these endonuclease impurities, according to the company. The kit also contains all the necessary, ready-to-use reagents for 96 analyses in microplate format, including a set of calibrated endonuclease standards. The assay can be easily integrated into desired workflow points-from process development to quality control to lot release testing.

Cygnus Technologies

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave A Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, CSO, AustinPx